Is Sunitinib effective in treating neuroendocrine tumors?

In November 2010, Sunitinib was approved by the European Commission for the treatment of adults with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression, 20 In May 2011, the U.S. Food and Drug Administration approved sunitinib for the treatment of patients with progressive neuroendocrine cancer tumors located in the pancreas that cannot be removed by surgery or have spread to other parts of the body (metastatic). The recommended dose of sunitinib is 37.5 mg, taken orally once daily until disease progression or unacceptable toxicity occurs. In order to control the adverse reactions caused by sunitinib, the initial dose was reduced to 25 mg once a day. If the drug is not tolerated, the drug will be discontinued.